Diagnostic performance of Liver FibraChek Dx©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer

This is the authors' abstract. We don't add key points for this paper.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, and cirrhosis are major risk factors for hepatocellular carcinoma (HCC), yet current blood-based diagnostic assays lack sufficient accuracy for routine clinical use. Identifying a non-invasive molecular signature that accurately detects liver disease could improve early diagnosis and monitoring. We hypothesized that the Liver FibraChek Dx© serum assay could discriminate MASLD and HCC from healthy controls using a multiplex biomarker-based algorithm. AIM To evaluate the diagnostic performance of the Liver FibraChek Dx© assay for detecting MASLD and HCC. METHODS This was a prospective, single-center study conducted in a United States tertiary care setting. Serum samples were collected from 45 participants (14 MASLD, 19 HCC, 12 healthy controls) with liver histology confirmed by biopsy. The Liver FibraChek Dx© algorithm integrates weighted values of aspartate aminotransferase, alanine aminotransferase, taurocholic acid, L-tyrosine, platelet count, and patient age to generate a risk score. Wilcoxon rank sum tests were used to assess associations with histologic diagnosis, and receiver operating characteristic (ROC) curves quantified diagnostic performance. RESULTS Liver FibraChek Dx© risk scores were significantly elevated in MASLD and HCC compared to controls (median: 6.92 ± 3.86 vs 3.61 ± 1.67, P < 0.001). The area under the ROC curve was 0.890 (95%CI: 0.776–1.000) for distinguishing diseased from healthy individuals. Sensitivity was 93.9%, specificity 75.0%, positive predictive value 91.1%, negative predictive value 81.8%, and overall accuracy 88.9%. CONCLUSION The Liver FibraChek Dx© assay accurately detects liver disease and shows promise as a non-invasive tool for diagnosing and monitoring MASLD and HCC.